Corcept Therapeutics (NASDAQ:CORT) just reported results for the second quarter of 2024.
- Corcept Therapeutics reported earnings per share of 32 cents. This was above the analyst estimate for EPS of 23 cents.
- The company reported revenue of $163.77 million.
- This was 5.50% better than the analyst estimate for revenue of $155.23 million.